Pricing Pressures And Competitive Risks Will Impair Market Strength

Key Takeaways

• Dependence on BRIUMVI exposes the company to competitive pressures, regulatory risks, and potential loss of pricing power, threatening revenue growth and market share.
  
• Rising operational costs and looming patent expiration increase margin pressure and vulnerability to revenue decline as generic and biosimilar competition intensifies.
  
• Strong commercial momentum for BRIUMVI, strategic diversification, disciplined spending, and effective market expansion position TG Therapeutics for robust, sustainable revenue and earnings growth.

Catalysts

A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

• Heightened global drug pricing scrutiny and potential for regulatory reforms threaten to erode pricing power for BRIUMVI, especially as healthcare budgets tighten; this could significantly constrain revenue growth and lead to margin compression even if prescription volumes rise.
  
• Persistently rising healthcare costs and increased payer pushback in the U.S. are likely to result in stricter reimbursement dynamics, potentially restricting patient access to novel MS therapies and directly capping or reducing future sales despite continued product awareness initiatives.
  
• The heavy reliance on BRIUMVI for revenue-combined with a narrow commercial portfolio and slow pipeline progression-leaves TG Therapeutics extremely exposed to competitive threats from established branded IV and newer subcutaneous options, which may lead to market share losses and declining top-line revenues as the anti-CD20 class matures.
  
• Mounting operational costs from R&D spending on formulation changes (such as subcutaneous development and delivery device bridging) and the need for broad commercial investments, like national media campaigns, are likely to put sustained pressure on net margins, particularly as price concessions to government programs deepen and as payer discounts increase in the hospital segment.
  
• Long-term, the looming patent cliffs on flagship therapies like BRIUMVI around 2029 and intensifying generic and biosimilar competition across the specialty pharma landscape could result in sharp post-exclusivity revenue declines and further depress earnings, leaving the business model highly vulnerable to abrupt financial contraction.

TG Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on TG Therapeutics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming TG Therapeutics's revenue will grow by 27.8% annually over the next 3 years.
• The bearish analysts assume that profit margins will shrink from 66.0% today to 41.1% in 3 years time.
• The bearish analysts expect earnings to reach $600.9 million (and earnings per share of $2.66) by about July 2029, up from $461.9 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $690.6 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 5.3x on those 2029 earnings, down from 16.8x today. This future PE is lower than the current PE for the US Biotechs industry at 17.3x.
• The bearish analysts expect the number of shares outstanding to decline by 2.86% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.28%, as per the Simply Wall St company report.

Risks

• BRIUMVI is experiencing strong uptake and commercial momentum in a growing multi-billion dollar U.S. MS market, with the company capturing roughly one-third of new IV anti-CD20 patient starts, driving continued top-line revenue growth.
  
• The shift towards self-administered therapies is being directly addressed by TG through the development of a subcutaneous BRIUMVI option, which is expected to unlock access to 35–40 percent of the market currently preferring this formulation, enabling significant future expansion in addressable market size and supporting long-term revenue growth.
  
• The ongoing expansion into related indications-such as advancing BRIUMVI into myasthenia gravis and exploring novel CAR-T cell therapies-gives TG the potential for product diversification and new revenue streams, which can improve portfolio durability and earnings over time.
  
• TG's operational execution and discipline in managing operating expenses, while already delivering GAAP profitability and maintaining a robust balance sheet, suggest the potential for sustained net margin improvement as the company transitions from launch to full-scale commercialization.
  
• The company's multichannel commercial strategy-including increased physician and patient awareness campaigns and growing provider preference across care settings-strengthens the brand position of BRIUMVI, supporting both pricing resilience and persistent patient demand, which may drive stronger long-term earnings and revenue stability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for TG Therapeutics is $20.0, which represents up to two standard deviations below the consensus price target of $58.38. This valuation is based on what can be assumed as the expectations of TG Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $83.0, and the most bearish reporting a price target of just $20.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $1.5 billion, earnings will come to $600.9 million, and it would be trading on a PE ratio of 5.3x, assuming you use a discount rate of 7.3%.
• Given the current share price of $54.87, the analyst price target of $20.0 is 174.4% lower.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.